Sayantan Maji

Sayantan Maji

Auto-generated profile, based on publicly available information

Sayantan Maji

Department of Medicine, University of Florida, Gainesville, FL

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2016 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
SMSayantan Maji
Sayantan Maji
IYIrene K. Yan
Irene K. Yan
MPMansi Parasramka
Mansi Parasramka
SMSwathi Mohankumar
Swathi Mohankumar
AMAkiko Matsuda
Akiko Matsuda
TPTushar Patel
Tushar Patel

1 December 2015 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
SMSayantan Maji
Sayantan Maji
ALAnn Marilyn Leitch
Ann Marilyn Leitch
IAIrina Akopova
Irina Akopova
PNPhung Nguyen
Phung Nguyen
Jamboor VishwanathaJamboor Vishwanatha
Jamboor Vishwanatha
Background: Early detection of cancer using circulating biomarkers is a realistic possibility with the discovery of exosomes. Cells under both physiological and pathological conditions secrete a wide array of membranous vesicles containing specific protein and RNA signatures. Exosomes, which are 40-100 nm in size, comprise a major portion of these vesicles. Exosomes play important roles in promoting tumor progression and metastasis, but the mechanisms by which they act are not yet understood. Annexin A2 (AnxA2) is a 36 kDa calcium dependent phospholipid-binding protein up-regulated in many cancer types and promotes tumorigenesis and angiogenesis by acting as a receptor for angiostatin and tissue plasminogen activator (t-PA) leading to plasmin mediated angiogenesis and metastasis. Recently, it was found that AnxA2 is one of the most commonly expressed proteins in exosomes, but its function has never been characterized. We propose to explore the correlation and functionality of exosome associated AnxA2 (exo-AnxA2) in breast cancer.

5 November 2020 in Blood
Verified
Journal Article
Open access
DDDaphne Dupere-Richer
Daphne Dupere-Richer
SMSayantan Maji
Sayantan Maji
ARAlberto Riva
Alberto Riva
GQGabrielle Quickstad
Gabrielle Quickstad
MKMarta Kulis
Marta Kulis
JLJonathan D. D Licht
Jonathan D. D Licht
Background: In multiple myeloma (MM), inactivating mutations and loss of the histone demethylase KDM6A (also named UTX, Ubiquitously transcribed Tetratricopeptide repeat, X chromosome) locus are found in up to 50% of patients and are associated with poorer prognosis. KDM6A belongs to a family of Jumonji-C (Jmj-C)-containing demethylases that work as a scaffold for a multiprotein complex containing H3K4 specific methyltransferases KMT2D and/or KMT2C (MLL2/3), the histone acetyltransferase CBP/p300 and members of the SWI/SNF chromatin-remodeling complex. In a concerted manner this complex activates enhancers by adding activation marks on histones and removing methylation of lysine 27 on histone H3 (H3K27me) associated with gene repression. The H3K27me3 methyltransferase EZH2 that catalyzes the reverse reaction of KDM6A, is often overexpressed in MM and this also correlates with poor prognosis. As well, KMT2C, KMT2D and SWI/SNF components of its complex are all found significantly mutated in MM which emphasize the importance of enhancer deregulation in myeloma. Aim: Our goal is to understand how loss of KDM6A affects gene transcription networks and enhancer function to affect MM pathogenesis or progression. Method: We explored the transcriptional consequences of KDM6A deficiency in patient tumors using the gene expression dataset included within the Multiple Myeloma Research Foundation (MMRF) Researcher Gateway and in MM cell lines using data from the Cancer Cell Line Encyclopedia (CCLE). We further modeled the loss of KDM6A in female MM cell lines using CRISPR-Cas9 ribonucleotide protein (RNP) technology and by re-expressing KDM6A in cells null for KDM6A. Using ChIP-sequencing analysis in isogenic KDM6A knockout or replete cell lines, we identified KDM6A binding site in MM and explored how KDM6A deficiency affects chromatin structure to regulate a transcriptional network. Results: Epithelial-to-mesenchymal-transition (EMT)-related pathways were downregulated in low KDM6A expressing tumor from the MMRF patient cohort. In both male and female patients, low expression of KDM6A was associated with decreased expression of genes involved in immune recognition. In MM cell lines, we observed a significant positive correlation between KDM6A expression level and expression of the transcriptional regulators of Major Histocompatibility complex I and II (MHCII and MCHII), NLRC5 and CIITA, respectively. With ChIP-sequencing analysis we find that KDM6A directly binds NLRC5 and CIITA genes, among many other genes involved in immune surveillance. KDM6A null MM cells displayed upregulation of pathways promoting EMT and downregulation of genes regulating immune function, such as HLA-A/B/C, CCL3/5, HHLA2 and ITGAL. Moreover, re-expression of KDM6A in KDM6A null cells upregulated the expression of these gene along with surface expression of MHCI proteins. Conclusion: Together, our data demonstrates that KDM6A modulates EMT and directly regulates expression of major regulators of immune surveillance. KDM6A deficiency may drive MM towards an EMT program to promote systemic spread and facilitate escape from the immune surveillance.

3 April 2023
Verified
Other
Open access
SMSayantan Maji
Sayantan Maji
PCPankaj Chaudhary
Pankaj Chaudhary
IAIrina Akopova
Irina Akopova
PNPhung M. Nguyen
Phung M. Nguyen
RHRichard J. Hare
Richard J. Hare
Jamboor VishwanathaJamboor Vishwanatha
Jamboor Vishwanatha

3 April 2023
Verified
Other
Open access
SMSayantan Maji
Sayantan Maji
PCPankaj Chaudhary
Pankaj Chaudhary
IAIrina Akopova
Irina Akopova
PNPhung M. Nguyen
Phung M. Nguyen
RHRichard J. Hare
Richard J. Hare
Jamboor VishwanathaJamboor Vishwanatha
Jamboor Vishwanatha

3 April 2023
Verified
Other
Open access
SMSayantan Maji
Sayantan Maji
PCPankaj Chaudhary
Pankaj Chaudhary
IAIrina Akopova
Irina Akopova
PNPhung M. Nguyen
Phung M. Nguyen
RHRichard J. Hare
Richard J. Hare
Jamboor VishwanathaJamboor Vishwanatha
Jamboor Vishwanatha
Quantification of angiogenic response by exosomal AnxA2